Navigation Links
Mercury Therapeutics Patents Filed
Date:3/31/2008

Patents Filed on Lead Compounds That Directly and Specifically Activate

AMPK

WOBURN, Massachusetts, March 31 /PRNewswire/ -- Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has filed for patent protection on three lead compounds that directly and specifically activate AMP activated protein kinase (AMPK).

The compounds are strong candidates for further development in relation to the treatment of Type-2 Diabetes and the Metabolic Syndrome, where AMPK activation is considered to be a key therapeutic target. MTI's lead compounds bind to a sub-unit of AMPK that is unique among human protein kinases.

The three lead compounds have been tested in obese mice, maintained on a high fat diet, which displayed elevated fasting blood glucose levels and a sluggish response in a glucose tolerance test (GTT). The statistically significant test results (p<0.05) showed a lowering of fasting blood glucose levels and improved performance in a GTT, without any apparent adverse effects.

MTI's proprietary integrated AMPK discovery platform technology has been central to identifying novel chemical scaffolds that have resulted in identifying multiple AMPK activators and inhibitors, and it is continuing to produce additional active molecules.

MTI will be presenting pre-clinical data in relation to Type-2 Diabetes and Metabolic Syndrome at the Spring BIO-Europe Conference in Madrid during April 7-9, 2008.

Neal C. Birnberg, Ph.D., Mercury Therapeutics' President and CEO, said: "MTI's program to develop an orally available AMPK activator has the potential to re-write the rules of how Type-2 Diabetes is managed. The mechanism of action through which AMPK normalizes metabolism will also create markets to treat the pre-diabetic state known as Impaired Glucose Tolerance, as well as the Metabolic Syndrome. With a continuation of the rapid progress MTI has made in the design and synthesis of novel AMPK activators, I am optimistic that we will be filing an IND by the end of 2009 to initiate clinical trials focusing on Type-2 diabetics who no longer respond to metformin or other available oral therapies."

About Mercury Therapeutics, Inc. (http://www.mtipharm.com)

MTI is an early stage drug discovery company focusing on the development of small molecule candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. MTI's main focus is on the discovery and development of orally active small molecule activators of AMPK, a well-validated though largely unexploited, protein kinase drug target in metabolic disease. While a number of anti-diabetic drugs currently on the market, including metformin (Glucophage(R)) and pioglitazone (Actos(R)), act indirectly to activate AMPK, MTI is seeking to develop the first orally available direct AMPK activator. The potential indications of a successful AMPK targeted drug include Type-2 diabetes, hyperlipidemia, obesity, metabolic syndrome and endocrine cancers.

MTI was launched in 2001, and has an exclusive license to a patent from Dartmouth College and St. Vincent's Institute for Biomedical Research in Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001, MTI launched its R&D operations following execution of a collaboration agreement with Aventis, AG to develop AMPK activators to treat Type-2 diabetes and obesity. In June 2004, Aventis was acquired by Sanofi, and MTI re-acquired all of its intellectual property rights to AMP kinase as well as the rights to develop compounds identified during the collaboration. In October, 2004: MTI secured external financing from XL TechGroup, Inc. In Q4 2005, MTI demonstrated its first preclinical proof-of-principle of active compounds in a glucose tolerance test in mice.

For further information:

Mercury Therapeutics Inc.

Stan Yakatan, Chairman

Tel: +1-786-229-9795

syakatan@aol.com

For Business Development enquiries:

Marquant Partners LLC

Joy Barton, Ph.D, Partner

Tel: +1-561-271-5311

jbarton@marquantpartners.com

http://www.marquantpartners.com


'/>"/>
SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
Breaking Biology Technology:
(Date:8/15/2017)... 15 2017   ivWatch LLC , a medical device company ... today announced receipt of its ISO 13485 Certification, the global standard ... Organization for Standardization (ISO®). ... Model 400 Continuous Monitoring device for the early detection of IV ... "This is an important milestone for ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
Breaking Biology News(10 mins):